Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- 28 August 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (17), 7828-7840
- https://doi.org/10.1021/jm300884k
Abstract
Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes. In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition of known inhibitors. A search of the Cambridge Structural Database using a series of pharmacophore queries led to the discovery of an O-spiroketal C-arylglucoside scaffold. Subsequent chemical examination combined with computational modeling resulted in the identification of the clinical candidate 16d (CSG452, tofogliflozin), which is currently under phase III clinical trials.Keywords
This publication has 43 references indexed in Scilit:
- 5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetesBioorganic & Medicinal Chemistry, 2011
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 InhibitorsJournal of Medicinal Chemistry, 2011
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humansKidney International, 2011
- SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathyJournal of Molecular and Cellular Cardiology, 2010
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010
- SGLT1 is a novel cardiac glucose transporter that is perturbed in disease statesCardiovascular Research, 2009
- Dapagliflozin: an emerging treatment option in type 2 diabetesExpert Opinion on Investigational Drugs, 2009
- The Crystal Structure of a Sodium Galactose Transporter Reveals Mechanistic Insights into Na + /Sugar SymportScience, 2008
- Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94Journal of Computational Chemistry, 1996